Skip to main content

Eli Lilly and Company Rest of world revenue

  • LLY · NYSE
  • Pharmaceuticals
  • S&P 500
$1443.50+1.14%Close 13 Nov 2026 · Market value $1.36T

Rest of world revenue at Eli Lilly and Company came to $3.2B for the quarter to 30 Sep 2026, up 89.9% from a year earlier.

As Eli Lilly and Company reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 29 Oct 2026.

By quarter

$744.4MDec 2023$892.9MMar 2024$1.2BJun 2024$1.1BSep 2024$1.1BDec 2024$997.0MMar 2025$1.2BJun 2025$1.7BSep 2025$2.2BDec 2025$2.8BMar 2026$2.9BJun 2026$3.2BSep 2026
Eli Lilly and Company Rest of world revenue, every reported period
Period endingRest of world revenueChange on a yearFiled
30 Sep 2026$3.2Bup 89.9%29 Oct 2026
30 Jun 2026$2.9Bup 143.4%5 Aug 2026
31 Mar 2026$2.8Bup 177.9%30 Apr 2026
31 Dec 2025$2.2Bup 105.8%12 Feb 2026
30 Sep 2025$1.7Bup 52.3%30 Oct 2025
30 Jun 2025$1.2Bdown 2.0%7 Aug 2025
31 Mar 2025$997.0Mup 11.7%1 May 2025
31 Dec 2024$1.1Bup 43.0%19 Feb 2025
30 Sep 2024$1.1Bup 42.0%30 Oct 2024
30 Jun 2024$1.2Bup 61.1%8 Aug 2024
31 Mar 2024$892.9Mup 32.7%30 Apr 2024
31 Dec 2023$744.4Mdown 9.5%21 Feb 2024
30 Sep 2023$780.3Mup 23.5%2 Nov 2023
30 Jun 2023$748.5Mup 15.9%8 Aug 2023
31 Mar 2023$673.1Mdown 10.4%27 Apr 2023
31 Dec 2022$822.9Mup 7.5%22 Feb 2023
30 Sep 2022$632.0Mdown 8.3%1 Nov 2022
30 Jun 2022$645.7Mup 1.2%4 Aug 2022
31 Mar 2022$751.5Mup 23.4%29 Apr 2022
31 Dec 2021$765.5Mup 17.0%23 Feb 2022
30 Sep 2021$689.4Mup 18.2%27 Oct 2021
30 Jun 2021$638.1Mup 10.9%3 Aug 2021
31 Mar 2021$609.1Mdown 0.2%30 Apr 2021
31 Dec 2020$654.0Mup 2.3%17 Feb 2021
30 Sep 2020$583.2Mdown 0.7%28 Oct 2020
30 Jun 2020$575.2Mup 0.6%31 Jul 2020
31 Mar 2020$610.4Mup 11.8%1 May 2020
31 Dec 2019$639.4M—19 Feb 2020
30 Sep 2019$587.3M—25 Oct 2019
30 Jun 2019$571.9M—2 Aug 2019
31 Mar 2019$546.2M—2 May 2019

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Eli Lilly and Company: Cardiometabolic Health revenue · Zepbound revenue · Mounjaro revenue · Oncology revenue · Verzenio revenue · Immunology revenue · Jardiance revenue · Trulicity revenue · Taltz revenue · Neuroscience revenue · United States revenue · Outside U.S. revenue · Europe revenue · China revenue · Japan revenue · financial statements

Every KPI and segment of LLY, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.